Longevity Peptide Research (2026)

The anti-aging peptide landscape has shifted significantly in 2025-2026. Here are the key developments relevant to the Midas Longevity Protocol compounds.

FOXO4-DRI: Expanded Applications

New 2025 research in Communications Biology demonstrated FOXO4-DRI efficacy in keloid treatment, expanding validated tissue types for this senolytic approach. Combined with continued validation across aging models, FOXO4-DRI is now the most comprehensively studied peptide senolytic.

SS-31 (Elamipretide): Clinical Advancement

SS-31 remains the most clinically advanced anti-aging peptide, with ongoing Phase 2/3 trials for Barth syndrome, heart failure, and age-related macular degeneration. The mitochondrial cardiolipin stabilization mechanism is now well-validated in human tissue.

NAD+ Restoration: Human Validation

Multiple 2025-2026 studies have confirmed that NAD+ levels are measurably restorable in humans, with corresponding improvements in sirtuin activity biomarkers. The field has moved beyond "does it work?" to optimizing delivery and timing.

Autophagy-Longevity Connection

Growing centenarian biomarker data linking beclin-1 levels to exceptional longevity provides human validation for autophagy-mediated longevity mechanisms. NAD+ (via SIRT1) is a key autophagy activator.

Thymosin Alpha-1: COVID-Era Validation

Post-pandemic research has expanded Thymosin Alpha-1's evidence base significantly, with multiple studies demonstrating immune reconstitution in aging populations.